Depo-Provera


Also found in: Thesaurus, Medical, Wikipedia.
Related to Depo-Provera: Depo-Medrol

Dep·o-Pro·ver·a

 (dĕp′ō-prō-vĕr′ə)
A trademark for a preparation of the drug medroxyprogesterone acetate.
References in periodicals archive ?
* Oral Contraceptive Pills * Injectable Birth Control (Depo-Provera) * Vaginal Ring (Nuva Ring) * Condoms As a trusted reproductive health care provider in Illinois for nearly 100 years, PPIL is taking the next steps to remove barriers that prevent patients from getting the care they need.
launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL single-dose vial, a generic version of the brand drag, Pfizer's Depo-Provera. The company is offering the new generic to its institutional customers after an Abbreviated New Drag Application (ANDA) for the product was approved by the FDA.
Mylan NV (NASDAQ: MYL), a global pharmaceutical company, announced yesterday that it has launched its Medroxyprogesterone Acetate Injectable (MPA) Suspension USP, 150mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera, in the United States.
C.J.R (2) addresses the Denver Probate Court's authorization of chemical castration by means of involuntarily administering Depo-Provera to a male patient exhibiting inappropriate and aggressive sexual behavior.
Progestin-only regimens can be given as a pill (norethindrone acetate) or by injection (Depo-Provera [medroxyprogesterone]).
He states that in users of Depo-Provera, estrogen levels fall to levels that are found in postmenopausal women, creating a potential for loss of bone mass.
Primary outcome of the analysis was to determine the contraceptive method used the most recent time a female had sexual intercourse: either LARC--via an intrauterine device or an implant--oral contraceptives; Depo-Provera, a patch, or a ring.
The study, an analysis of 12 observational trials, says there is a 40 per cent increase in the risk of HIV infection in women using Depo-Provera compared to women using a non-hormonal contraceptive and those not practicing brith control.
All the participants acknowledged knowing about the male condom; as to other methods of contraception, 41 (93.2%) knew about oral contraceptive pills (OCPs), 31 (70.5%) knew about the patch, 30 (68.2%) knew about Depo-Provera, and 25 (56.8%) knew about intrauterine devices (IUD).
For example, Solinger's response only refers to the intramuscular hormonal injectable contraceptive Depo-Provera and the discontinued subdermal implant Norplant as politically controversial LARC methods.
The bone loss observed in adolescents and young women who use depot medroxy-progesterone acetate (Depo-Provera) for contraception led to an FDA-mandated boxed warning on the medication's package insert.